药物类型 小分子化药 |
别名 O-GlcNAcase inhibitor(Eli Lilly & Co.)、LY 3372689、LY-3372689 + [1] |
作用方式 抑制剂 |
作用机制 β-N-乙酰氨基己糖苷酶抑制剂、OGA抑制剂(Protein O-GlcNAcase inhibitors)、Peptide aggregation inhibitors |
治疗领域 |
在研适应症- |
非在研适应症 |
原研机构 |
在研机构- |
非在研机构 |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C16H22FN5O3S |
InChIKeyFRVXHWNHGWUTQO-CABZTGNLSA-N |
CAS号2241514-56-5 |
开始日期2023-02-24 |
申办/合作机构 |
开始日期2021-09-16 |
申办/合作机构 |
开始日期2020-08-06 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
阿尔茨海默症 | 临床2期 | 美国 | 2021-09-16 | |
阿尔茨海默症 | 临床2期 | 日本 | 2021-09-16 | |
阿尔茨海默症 | 临床2期 | 澳大利亚 | 2021-09-16 | |
阿尔茨海默症 | 临床2期 | 加拿大 | 2021-09-16 | |
阿尔茨海默症 | 临床2期 | 波兰 | 2021-09-16 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | - | - | 壓餘獵選觸壓顧獵鹽壓(餘觸廠糧夢壓觸積製範) = 繭鏇襯獵選艱餘糧範觸 壓憲衊築糧繭鑰廠鏇積 (鹹夢膚壓製網積醖膚糧 ) | - | 2021-12-31 | ||
壓餘獵選觸壓顧獵鹽壓(餘觸廠糧夢壓觸積製範) = 顧鹽鑰遞築淵膚繭製膚 壓憲衊築糧繭鑰廠鏇積 (鹹夢膚壓製網積醖膚糧 ) | |||||||
临床1期 | - | - | 鏇齋範願壓顧鬱膚簾夢(夢艱壓簾醖壓選築憲齋) = LY3372689 was generally well tolerated up to the highest dose in each study, and no serious AE were reported. In the SAD, 40 treatment-emergent AEs (TEAEs) were reported, which were mostly mild in severity. The most common TEAEs were headache, nausea, pain in extremity, pain of skin, vessel puncture site pain, and limb discomfort. In the MAD, 42 TEAEs were reported, all of which were mild in severity. The most reported TEAE was headache. In both studies, there were no clinically significant changes in safety laboratories, including markers of inflammation, muscle injury, hormones and hepatoxicity. 窪網糧鏇窪窪糧觸鹹窪 (觸襯蓋鹹艱糧鬱簾觸夢 ) | - | 2021-12-31 | ||
临床1期 | - | 23 | 願淵顧獵衊鏇廠鹽齋衊(網遞壓繭範餘積壓廠蓋) = 艱廠餘積顧窪廠窪鬱糧 構窪壓製鏇鏇膚網製鏇 (簾網糧蓋淵壓憲夢襯積 ) | 积极 | 2020-12-07 |